Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review

Abstract Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relie...

Full description

Saved in:
Bibliographic Details
Main Authors: Hong-Bo Li, Zi-Han Yang, Qing-Qu Guo
Format: article
Language:EN
Published: BMC 2021
Subjects:
R
Online Access:https://doaj.org/article/406634dabe0244e6958f3f3e3ac6d2be
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items